Inhaltsbereich
| 7 Einträge |
Seite 1 / 1
 Druckansicht
|
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. |
| Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F |
| The Lancet. Oncology. 2019 Feb 11. pii: S1470-2045(18)30812-X. doi: 10.1016/S1470-2045(18)30812-X |
| PMID: 30765258 |
| CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an pro and con discussion. |
| Awada A, Gligorov J, Jerusalem G, Preusser M, Singer C, Zielinski C |
| ESMO open. 2019 Nov 13. doi: 10.1136/esmoopen-2019-000565. pii: esmoopen-2019-000565. pmc: PMC6863664 |
| PMID: 31798979 |
| A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. |
| Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J |
| Breast cancer research : BCR. 2021 Jan 15. doi: 10.1186/s13058-020-01382-8. pii: 10.1186/s13058-020-01382-8 |
| PMID: 33451345 |
| Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. |
| Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G |
| JCO global oncology. doi: 10.1200/GO.20.00589 |
| PMID: 33529077 |
| Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. |
| Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D |
| Cancers. 2021 Sep 1. pii: cancers13174421. doi: 10.3390/cancers13174421 |
| PMID: 34503231 |
| Expert Discussion: SABCS 2021. |
| Bartsch R, Kolberg-Liedtke C, Jerusalem G, Palmieri C, Janni W |
| Breast care (Basel, Switzerland). 2022 Jan 4. doi: 10.1159/000521762. pii: brc-0017-0101. pmc: PMC8914229 |
| PMID: 35355701 |
| 7 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
